NAMSA, Terumo Aortic Begin Strategic Outsourcing Partnership

NAMSA, a medtech contract research organization (CRO) and Terumo Aortic have entered a strategic outsourcing partnership to help with acceleration and commercialization of Terumo Aortic’s aortic disease products.
 
Terumo Aortic manufactures device to treat thoracic and abdominal aneurysms, as well as acute and chronic dissections. The organization operates in over 100 countries around the world.
 
“NAMSA could not be more pleased to announce the news of this strategic outsourcing partnership to facilitate growth for Terumo Aortic,” Christophe Berthoux, NAMSA CEO told the press. “As part of this partnership, we have guaranteed Terumo Aortic immediate access to clinical experts for study starts and capacity, in addition to accessing our skilled and talented teams of cardiovascular-focused experts. We are honored to play a leading role in helping Terumo Aortic accelerate the introduction of life-enhancing devices.”
 
NAMSA’s strategic outsourcing solution and suite of development services under one roof offers medtech innovators proactive planning and risk mitigation, capital preservation, and creation of stakeholder alignment. This leads to accelerated to commercialization.
 
John Canning, COO of Terumo Aortic, commented, “We look forward to our strategic outsourcing partnership with NAMSA. They will play a vital role in our product development and this partnership will enable Terumo Aortic to accelerate the commercialization of our products. NAMSA will allow us to bring the latest technology and innovation to physicians and patients faster.”
 
This outsourcing collaboration with Terumo Aortic is the CRO’s second such partnership, with the first announced in September 2022.